Score Overview
Explore the 2021 public Archive ranking →
Where Amneal Pharmaceuticals, Inc. Class A Common Stock has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. AMRX does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-23 | $ 20.38 | — |
1 Year2025-10-23 | $ 10.42 | 95.59% |
5 Years2021-10-22 | $ 5.67 | 259.44% |
10 Years2016-10-21 | $ 21.85 | -6.73% |
All Time2009-01-15 | $ 4.75 | 329.05% |
| Period | Last Price2026-10-23 | 1 Year2025-10-23 | 5 Years2021-10-22 | 10 Years2016-10-21 | All Time2009-01-15 |
|---|---|---|---|---|---|
| Price | $ 20.38 | $ 10.42 | $ 5.67 | $ 21.85 | $ 4.75 |
| Return | — | 95.59% | 259.44% | -6.73% | 329.05% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 3.11B | $ 157M | $ 127M |
| 2025 | $ 3.01B | $ 72M | $ 310M |
| 2024 | $ 2.79B | -$ 116M | $ 112M |
| 2023 | $ 2.39B | -$ 83M | $ 93M |
| 2022 | $ 2.21B | -$ 129M | $ 27M |
| 2021 | $ 2.09B | $ 10M | $ 247M |
| 2020 | $ 1.99B | $ 91M | $ 343M |
| 2019 | $ 1.62B | -$ 361M | $ 152M |
| 2018 | $ 1.66B | -$ 169M | $ 213M |
| 2017 | $ 1.03B | $ 167M | $ 74M |
| 2016 | $ 1.01B | $ 207M | $ 31M |
| 2015 | $ 866M | $ 169M | $ 66M |
| 2014 | $ 785M | $ 176M |
Amneal Pharmaceuticals, Inc. Class A Common Stock fundamental performance
Between 2020 and 2025, revenue grew from $ 1.99B to $ 3.01B and net income declined from $ 91M to $ 72M. Revenue increased in every one of those 5 years; net income in 3.
Across Amneal Pharmaceuticals, Inc. Class A Common Stock's full reported history, from 2014 to 2025, revenue grew from $ 785M to $ 3.01B and net income declined from $ 176M to $ 72M. Revenue increased in 92% of the years measured; net income in 42%.
Amneal Pharmaceuticals, Inc. Class A Common Stock currently holds a 5-year HDB Score of 7.3 out of 10. How the HDB Score is calculated.
Membership
Explore AMRX with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,112 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
